The NephroCheck Test
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3550 General Atomics Ct Bldg 2-620, San ...Phone Number
(858) 500-7000Website
www.nephrocheck.comRevenue
$6.1 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About The NephroCheck Test
bioMérieux specializes in pioneering diagnostics, particularly with their VIDAS® NEPHROCHECK® assay, which measures urinary biomarkers TIMP-2 and IGFBP-7 for early risk assessment of acute kidney injury (AKI). Their products are designed to assist clinicians in evaluating patients who are acutely ill, especially those in intensive care settings. The company targets healthcare professionals and institutions, providing tools that enhance patient care and safety. With a commitment to innovation, bioMérieux aims to improve health outcomes through advanced diagnostic solutions.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is The NephroCheck Test your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when The NephroCheck Test launches new products
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on The NephroCheck Test recently announced quarterly report
Check out if The NephroCheck Test is spiking on competitors!
Check if The NephroCheck Test has recently received funding, and reach out quickly before it becomes old news!
The NephroCheck Test, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if The NephroCheck Test had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at The NephroCheck Test
Funding: Get notified immidiatlly once The NephroCheck Test has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to The NephroCheck Test
Compare insights from companies similar to The NephroCheck Test, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
The NephroCheck Test
$6.1M
11-50
Private
-
-
N/A
Company Profile Activity
Activity Insights
The NephroCheck Test is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
The NephroCheck Test is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about The NephroCheck Test.
The NephroCheck Test Tech Stack
A closer look at the technologies used by The NephroCheck Test
The NephroCheck Test News & Media
Astute Medical To Exhibit At Society Of Thoracic Surgeons Annual Meeting
SAN DIEGO, Jan. 26, 2018 /PRNewswire/ -- Astute Medical, Inc., developer of biomarkers for better healthcare, announced today that it will be exhibiting at the Society of Thoracic Surgeons (STS) 54th Annual Meeting at the Broward County Convention Center in Fort Lauderdale, Florida, from...Test For AKI Risk Assessment Could Lead To Safer ICU Care
SAN DIEGO, Dec. 27, 2017 /PRNewswire/ -- Hospital clinicians have long been frustrated by the prospect of intensive care unit (ICU) patients developing acute kidney injury (AKI), a stealthy and potentially deadly condition that can arise from renal insults stemming from treatments and...
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding The NephroCheck Test
Sign Up For FreeTo access detailed company insights
bioMérieux specializes in pioneering diagnostics, particularly with their VIDAS® NEPHROCHECK® assay, which measures urinary biomarkers TIMP-2 and IGFBP-7 for early risk assessment of acute kidney injury (AKI). Their products are designed to assist clinicians in evaluating patients who are acutely ill, especially those in intensive care settings. Th... Read More
